Pancreas Cancer Academy 2022
CECOG Academy
Case Review of a 78 y/o Man With PDAC: Following OS From the Start of Adjuvant Chemotherapy
FEATURING
Florian Huemer
- 109 views
- September 7, 2022
CECOG Academy
Case Review: Fit Patient With mPDAC
FEATURING
Hossein Taghizadeh
- 18 views
- September 7, 2022
CECOG Academy
1L mPDAC & Sequence Debate: Why Gemcitabine & Nab-Paclitaxel Followed by FOLFIRINOX Is a Good Option
FEATURING
Harpreet Wasan
- 11 views
- September 7, 2022
CECOG Academy
mPDAC Treatment Debate: FOLFIRINOX Followed by Gemcitabine + Nab-Paclitaxel
FEATURING
Julien Taieb
- 12 views
- September 7, 2022
CECOG Academy
mPDAC Sequence Debate: Albumin-Bound Paclitaxel / Gemcitabine Followed by 5-FU-LV / nal-IRI
FEATURING
Gerald Prager
- 18 views
- September 7, 2022
CECOG Academy
New 2022 ESMO Guidelines for Pancreatic Cancer
FEATURING
Thierry Conroy
- 276 views
- September 7, 2022
CECOG Academy
Case Review: Borderline Resectable PDAC
FEATURING
Hossein Taghizadeh
- 51 views
- September 7, 2022
CECOG Academy
Borderline PDAC: What Is the Best Neoadjuvant Treatment Concept?
FEATURING
Teresa Macarulla
- 66 views
- September 7, 2022
- 2
CECOG Academy
What to Do With PDAC Patients After Secondary Resection?
FEATURING
Harpreet Wasan
- 19 views
- September 7, 2022
CECOG Academy
How to Assess Resectability: The Surgeon's View
FEATURING
Oliver Strobel
- 23 views
- September 6, 2022
CECOG Academy
How to Pick the Individual (Neo)adjuvant Treatment Concept in Resectable PAC
FEATURING
Eric Van Cutsem
- 161 views
- September 6, 2022
CECOG Academy
Personalized Treatment Approach by Molecular Profiling Might Lead to Better Prognosis of mPDAC Patients
FEATURING
Talia Golan
- 52 views
- September 6, 2022